Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine.
Level 5 - mechanism / opinion, no new human data
Narrative review and clinical primer without systematic search methodology or original human data
PubMed 38518270 · doi:10.1097/MJT.0000000000001723
What was done
This narrative review summarizes clinical, pharmacological, and safety literature on ibogaine to inform primary care clinicians about its therapeutic potential and risks across substance use disorders, post-traumatic stress disorder (PTSD), depression, anxiety, and traumatic brain injury.
What was found
Synthesizing available research, the review reports that open-label and randomized studies demonstrate ibogaine reduces heroin and opioid cravings by upwards of 50% for up to 24 weeks following a single treatment. In an observational study of 30 Special Operations Forces veterans with mild traumatic brain injury, a single ibogaine dose yielded remission rates at one month of 86% for PTSD, 83% for depression, and 83% for anxiety. Crucially, the review notes severe safety concerns: QT interval prolongation with potential for fatal arrhythmias (which preliminary work suggests magnesium co-administration may mitigate), dangerous interactions requiring withdrawal from long-acting opioids prior to treatment, rare mania or psychosis, and transient ataxia, tremors, and gastrointestinal side effects. Only one double-blind, placebo-controlled randomized trial has been conducted to date.
Why it matters
Provides clinicians with a concise overview of ibogaine's preliminary efficacy in treatment-resistant neuropsychiatric conditions alongside essential guidance on its substantial cardiotoxicity and screening requirements.
Limits
This is a narrative primer rather than a systematic review or meta-analysis. The underlying evidence base is sparse, relying largely on small observational and open-label studies with only a single double-blind placebo-controlled trial published.
Cited by
- supports Electrolyte deficiency during an ibogaine session contributes to its cardiac toxicity.